Description: AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Home Page: www.astrazeneca.com
AZN Technical Analysis
1 Francis Crick Avenue
Cambridge,
CB2 0AA
United Kingdom
Phone:
44 20 3749 5000
Officers
| Name | Title |
|---|---|
| Mr. Pascal Soriot D.V.M., M.B.A. | CEO & Exec. Director |
| Dr. Aradhana Sarin M.D. | CFO & Exec. Director |
| Mr. Marc Dunoyer | CEO of Alexion & Chief Strategy Officer |
| Ms. Pam P. Cheng | EVP of Operations & Information Technology and Member of External Sustainability Advisory Board |
| Mr. Chris Sheldon | Head of Investor Relations |
| Mr. Jeffrey Pott | Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board |
| Ms. Katarina Ageborg | EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board |
| Gonzalo Vina | Head of Global Media Relations |
| Dr. Menelas Pangalos Ph.D. | EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board |
| Dr. Ruud Dobber Ph.D. | Exec. Vice-Pres of BioPharmaceuticals Bus. Unit |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 18.2815 |
|---|---|
| Trailing PE: | 106.7339 |
| Price-to-Book MRQ: | 6.1679 |
| Price-to-Sales TTM: | 3.8983 |
| IPO Date: | 1993-05-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 83100 |